Core Insights - Crofelemer has the potential to significantly extend and save the lives of patients with microvillus inclusion disease (MVID) by reducing the volume of total parenteral support (PS) necessary for their survival [1] - The groundbreaking reduction in PS volume of up to 37% is unprecedented, highlighting the drug's potential impact [1] - Currently, there are no approved treatments for MVID, making this development particularly noteworthy [1] Company and Industry Summary - Jaguar Health, Inc. (NASDAQ:JAGX) and its family company Napo Pharmaceuticals presented initial results from an independent investigator-initiated trial (IIT) of crofelemer at the NASPGHAN Annual Meeting [1] - The trial focused on pediatric intestinal failure, specifically targeting patients with MVID and short bowel syndrome (SBS-IF) [1] - MVID is characterized by the intestines not functioning properly, which is a common issue among patients with intestinal failure due to short bowel syndrome [1]